Instadose Pharma Corp.
INSD
Other OTC0.00
USD
- -
- -
CIK
0001697587
ISIN
US45783B1035
Return %
Stock
S&P500
1Y
-90.91
26.84
3Y
-90.91
77.03
5Y
-99.90
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Antonio Rocco Franchino
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1545 Crossways Blvd Chesapeake VA United States of America L7L 6W6
- IPO Date
- Oct 27, 2020
- CIK
- 0001697587
- Website
- instadosepharma.com
- Similar Companies
- Business
- Instadose Pharma Corp. operates as a pharmaceutical company specializing in the cultivation, production, marketing, and sale of medicinal cannabis and cannabinoid oil products. The company establishes and manages a global distribution platform designed to supply pharmaceutical industry companies with large, sustainable, and consistent bulk supplies of high-quality medicinal cannabis and cannabinoid oil for use as active pharmaceutical ingredients. Its product portfolio includes top-grade medicinal cannabis flower with high levels of delta-9-tetrahydrocannabinol (THC), catered primarily to pharmaceutical customers. Instadose Pharma Corp. has developed extensive strategic joint ventures and partnerships internationally for cultivation and distribution, including operations in Canada, Cameroon, India, Colombia, South Africa, North Macedonia, and Portugal. These efforts focus on expanding its medicinal cannabis supply chain through licensing, cultivation agreements, and import permits, notably securing a large-scale import permit for over two metric tons of medical cannabis from Southern Africa to North Macedonia. The company is enhancing its geographic presence across five continents with a continuous emphasis on building production facilities and import-export channels. Recent major developments include the acquisition of Instadose Canada, which serves as the operational hub for their Global Distribution Platform initiative. The company has also finalized strategic joint ventures in emerging markets such as India (Uttarakhand region) for hemp cultivation and in Colombia for medical cannabis export to Europe. Additionally, a new import location was established in Portugal to strengthen the company’s foothold within the European Union medicinal cannabis market. These moves align with Instadose’s strategic expansion to scale production and distribution capabilities globally. Founded in 2016 and headquartered in Toronto, Canada, Instadose Pharma Corp. operates primarily within the pharmaceutical and agricultural biotechnology industries. The company aims to serve Big Pharma and other pharmaceutical sector clients globally, with a focus on producing reliable and cost-efficient medicinal cannabis supply for pharmaceutical applications through its subsidiaries and joint ventures. Overall, Instadose Pharma Corp. maintains a comprehensive business model encompassing medicinal cannabis cultivation, production, global distribution, and strategic alliance formations aimed at pharmaceutical-grade product supply on a global scale, reflecting its latest expansions and acquisitions in the past two years.